- Home
- PETS vs BYSI Comparison
PETS vs BYSI Comparison
Compare PETS & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.04
HOLD
Current Price
$1.52
Company Overview
Basic Information| Metric | PETS | BYSI |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.9M | 79.0M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | PETS | BYSI |
|---|---|---|
| Price | $3.04 | $1.52 |
| Analyst Decision | Sell | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.20 | N/A |
| AVG Volume (30 Days) | ★ 207.8K | 39.8K |
| Earning Date | 02-02-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $198,265,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.57 | $0.98 |
| 52 Week High | $5.58 | $3.44 |
Technical Indicators
Market Signals| Indicator | PETS | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 39.73 |
| Support Level | $3.20 | $1.50 |
| Resistance Level | $3.52 | $1.64 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 3.00 | 18.52 |
Price Performance
Historical Comparison PETS
BYSI
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.